Персонифицированная химиотерапия: маркеры предсказания токсичности противоопухолевых препаратов
Аннотация
В настоящее время для лечения онкологических заболеваний используется множество химиотерапевтических препаратов, однако мало известно о маркерах, предсказывающих эффективность и токсичность лечения. Как было показано, вариабельность в эффективности и токсичности химиопрепаратов у отдельных больных определяют их генотипические особенности. В обзоре описываются основные ферменты, метаболизирующие ксенобиотики, а также их значение для предсказания токсичности современных химиопрепаратов и перспективы дальнейших исследований.
Об авторах
М. Е. Абрамов
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Россия
Россия
А. В. Шварова
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Россия
Россия
Е. В. Степанова
Российский онкологический научный центр им. Н.Н. Блохина РАМН
Россия
Россия
M. Abramov
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Россия
Россия
A. Shvarova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Россия
Россия
E. Stepanova
N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences
Россия
Россия
Список литературы
1. Bosnia P.J., Chowdhury J.R., Bakker С. et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 1995, v. 333, p. 1171-1175.
2. Calhoun E.A., Chang C.H., Welshman E.E.etal. Evaluating the total costs of chemotherapy-induced toxicity: results from a pilot study with ovarian cancer patients. Oncologist. 2001, v. 6, p. 441-445.
3. De Jong E., Scott-Horton T., Kroetz D. et al. Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 2007, v. 81, p. 42-49.
4. Evans W.E., Johnson J.A. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Ann. Rev. Genomics Hum. Genet. 2001, v. 2, p. 9-39.
5. Evans W.E., McLeod H.L. Pharmacogenomics. Drug Disposition, Drug Targets, and Side Effects. N. Engl. J. Med. 2003, v. 348, p. 538-549.
6. Hoskins J., Goldberg R., Qu P. et al. UGT1A1*28 genotype and irinotecan-induced neutropenia: dose matters. J. Natl. Cancer Inst. 2007, v. 99, p. 1290-1295.
7. Iyer L., King C., Whitington P. et al. Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1 Al in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J. Clin. Invest. 1998, v. 101, p. 847-854.
8. Kawakami K., Salonga D., Park J.M. et al. Different lengths of a polymorphic repeat sequence in the thymidylate synthase gene affect translational efficiency but not its gene expression. Clin. Cancer. Res. 2001, v. 7, p. 4096-4101.
9. Lecomte T., Ferraz J., Zinzindohouer F., et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin. Cancer. Res. 2004, v. 10, p. 5880-5888.
10. Lu Z., Zhang R., Diasio R. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res. 1993, v. 53, p. 5433-5438.
11. Malingre M.M., Beijnen J.H., Rosing H. et al. Co-administration of GF120918 significantly increases the systemic exposure to oral paclitaxel in cancer patients. Br. J. Cancer. 2001, v. 84, p. 42-47.
12. Marsh S. Taxane pharmacogenetics. Personalized Med. 2006. v. 3, p. 33-43.
13. Marsh S. Thymidylate synthase pharmacogenetics. Invest New Drugs. 2005, v. 23, p. 533-537.
14. McLeod H.L., Evans WE. Pharmacogenomics: unlocking the human genome for better drug therapy. Ann. Rev. Pharmacol. Toxicol. 2001, v. 41, p. 101-121.
15. Meyer U.A. Pharmacogenetics and adverse drug reactions. Lancet. 2000, v. 356, p. 1667-1671.
16. Mir O., Alexandre J., Tran A. et al. Relationship between GSTP1 Ile(105)Val polymorphism and docetaxel-induced peripheral neuropathy: clinical evidence of a role of oxidative stress in taxane toxicity. Ann. Oncol. 2009, Apr, v. 20 (4), p. 736-740.
17. Morel A., Boisdron-Celle M., Fey L. et al. Clinical relevance of different dihydropyrimidine dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol. Cancer Ther. 2006, v. 5, p. 2895-2904.
18. Ratain M.J. From bedside to bench to bedside to clinical practice: an odyssey with irinotecan. Clin. Cancer Res. 2006, v. 12, p. 1658-1660.
19. Rothenberg M. Efficacy and toxicity of irinotecan in patients with colorectal cancer. Semin. Oncol. 1998, v. 25 (5 suppl 11), p. 39-46.
20. Schwab M., Zanger U., Marx C. et al. Role of genetic and nongene tic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J. Clin. Oncol. 2008, v. 26, p. 2131-2138.
21. Sissunga T.M., Mrossb K., Steinbergc S.M. et al. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia. E. J. Cancer. 2006, v. 42, p. 2893-2896.
22. Watters J.W., McLeod H.L. Cancer pharmacogenomics: Current and future applications. Biochim. Biophys. Acta. 2003, v. 1603, p. 99-111.
23. WeiX., Elizondo G, Sapone A. etal. Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics. 1998, v. 51, p. 391-400.
24. Yen J., McLeod H. Should DPD analysis be required prior to prescribing fluoropyrimidines? Eur. J. Cancer. 2007, v. 43, p. 1011-1016.
Рецензия
Для цитирования:
Абрамов М.Е., Шварова А.В., Степанова Е.В., , , Персонифицированная химиотерапия: маркеры предсказания токсичности противоопухолевых препаратов. Саркомы костей, мягких тканей и опухоли кожи. 2011;(4):73-76.
For citation:
, , , Abramov M.E., Shvarova A.V., Stepanova E.V. TOWARDS INDIVIDUALIZED TREATMENT: PREDICTIVE FACTORS FOR CHEMOTHERAPY RELATED TOXIC EFFECT. Bone and soft tissue sarcomas, tumors of the skin. 2011;(4):73-76. (In Russ.)
Просмотров:
75
Послать статью по эл. почте 
